What are the side effects and contraindications of phentermine in an adult with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight‑related health problems)?

Phentermine Side Effects and Contraindications

Most Common Side Effects

Phentermine causes dry mouth, insomnia, constipation, and dizziness as its most frequent adverse effects, with dry mouth occurring in up to 21% of patients at the 15 mg dose. 1, 2

• Dry mouth is the single most common side effect reported across clinical trials 2
• Insomnia and sleep disturbances occur frequently; taking phentermine early in the morning (approximately 2 hours after breakfast) minimizes this risk 3, 2
• Constipation affects 15–17% of patients due to sympathomimetic effects 1, 4
• Dizziness occurs in approximately 10% of patients at higher doses 4, 2
• Dysgeusia (altered taste) affects roughly 10% of patients 4, 2
• Irritability and anxiety may develop, particularly in patients with pre-existing anxiety disorders 2, 4
• Paresthesias (tingling sensations) occur in approximately 21% of patients, especially when phentermine is combined with topiramate 4

Cardiovascular Effects

Phentermine produces mild sympathomimetic increases in heart rate and blood pressure, requiring cardiovascular monitoring at every clinical visit throughout treatment. 1, 5

• Phentermine elevates norepinephrine in the central nervous system, causing modest increases in heart rate and blood pressure 1, 2
• Paradoxically, observational data show that blood pressure often decreases during therapy (average reductions of approximately −7.3 mmHg systolic and −5.4 mmHg diastolic at 52 weeks), likely secondary to weight loss 5
• Blood pressure and heart rate must be measured at every clinical visit throughout treatment 5, 2
• Palpitations and tachycardia can occur as dose-dependent effects 2

Serious Adverse Events and Discontinuation Rates

Treatment discontinuation due to adverse events occurs at a rate of 17.4% with phentermine-topiramate combination therapy versus 8.5% with placebo (RR 2.08). 1

• Serious adverse events (SAEs) occurred in 4.2% of patients receiving phentermine-topiramate ER 15 mg/92 mg versus 3.5% with placebo 1
• Depression-related adverse events occurred in 7% of patients on the higher-dose combination 4
• Anxiety-related adverse events occurred in 8% of patients on the higher-dose combination 4

Absolute Contraindications

Phentermine is absolutely contraindicated in any patient with a history of cardiovascular disease, including coronary artery disease, stroke, arrhythmias (including atrial fibrillation), congestive heart failure, or uncontrolled hypertension. 6, 3

Cardiovascular Contraindications

• Any history of coronary artery disease 6, 3
• Any history of stroke 6, 3
• Any arrhythmias, including atrial fibrillation—even if currently controlled with a pacemaker, the contraindication remains because the underlying arrhythmic substrate is not eliminated by device therapy 6
• Congestive heart failure 6, 3
• Uncontrolled hypertension 6, 3

Drug Interaction Contraindications

• Current use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of MAOI discontinuation due to risk of hypertensive crisis 6, 3
• Concurrent use of other sympathomimetic amines due to additive cardiovascular stimulation 6, 3

Metabolic and Endocrine Contraindications

• Untreated hyperthyroidism due to risk of arrhythmias and seizures from additive sympathomimetic effects 6, 3

Ophthalmologic Contraindications

• Angle-closure glaucoma because sympathomimetic agents worsen intraocular pressure 6, 3

Psychiatric and Substance Use Contraindications

• Agitated states or active anxiety disorders may be exacerbated by phentermine's stimulant properties 6, 3
• History of drug abuse—phentermine is a Schedule IV controlled substance 6, 3

Pregnancy and Lactation

• Pregnancy (FDA Category X) is an absolute contraindication 2, 6, 3
• Lactation/nursing is contraindicated 3
• Women of childbearing potential without reliable contraception should not receive phentermine 6

Hypersensitivity

• Known hypersensitivity or idiosyncrasy to sympathomimetic amines 3

Use in Patients with Controlled Hypertension

Phentermine may be prescribed to patients whose hypertension is well-controlled (systolic <140 mmHg and diastolic <90 mmHg) on antihypertensive regimens that do NOT include MAO inhibitors, with mandatory ongoing cardiovascular monitoring. 5, 6

• Clinical trials enrolling participants with controlled baseline hypertension (<160/100 mmHg) found that blood pressure generally decreased during phentermine therapy 5
• Blood pressure and heart rate must be monitored at every visit 5

Pre-Treatment Evaluation Requirements

Before prescribing phentermine, obtain baseline blood pressure and heart rate, verify pregnancy status in all women of reproductive potential, conduct a complete medication review for MAOIs and sympathomimetics, and screen for cardiovascular disease, hyperthyroidism, glaucoma, psychiatric disorders, and substance-use history. 6

• Verify BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity 6
• Perform pregnancy screening with negative result in all women of reproductive potential 6
• Obtain detailed cardiovascular history, including remote history of arrhythmias or structural heart disease 6
• Assess thyroid function to exclude hyperthyroidism 6
• Review medications for MAOI exposure within 14 days, other sympathomimetics, and alcohol use 6
• Screen for glaucoma, psychiatric disorders (anxiety, agitation), and substance-use disorders 6

Perioperative Considerations

Phentermine should be discontinued at least 4 days before any procedure requiring anesthesia due to risk of refractory hypotension from catecholamine depletion and autonomic dysfunction. 1

• Phentermine acts as a reuptake inhibitor of norepinephrine, and refractory hypotension has been reported during anesthesia 1

Monitoring Protocol During Treatment

Measure blood pressure and heart rate at every clinical visit, assess body weight monthly for the first three months, then at least every three months thereafter, and discontinue if <5% weight loss after 12 weeks on maximum tolerated dose. 5, 6

• Continue phentermine only if the patient achieves ≥5% weight loss after 12 weeks 6
• Discontinue if <5% weight loss after 12 weeks on maximum dose 6
• No routine metabolic panels, lipid profiles, or liver function tests are mandated by current guidelines; focus remains on cardiovascular parameters and weight-loss efficacy 5

Duration of Use and Off-Label Prescribing

Although FDA-approved only for short-term use (12 weeks), many clinicians prescribe phentermine off-label for 3–6 months or longer because obesity is a chronic metabolic disease requiring long-term management. 5, 2

• The FDA approval for 12 weeks reflects historical regulatory constraints rather than safety concerns specific to phentermine monotherapy 5
• No large cardiovascular outcome trials exist for long-term phentermine monotherapy 2, 6
• Treatment decisions should be based on efficacy and ongoing cardiovascular safety monitoring rather than arbitrary time limits 5
• No mandatory washout period is required between treatment courses if prior discontinuation was for non-safety reasons 5

Critical Safety Clarification: Phentermine vs. Fen-Phen

Phentermine monotherapy should not be confused with the discontinued "fen-phen" combination; the valvular heart disease and pulmonary hypertension associated with fen-phen were caused by fenfluramine, not by phentermine. 5, 6

Safer Alternatives for High-Risk Patients

For patients with cardiovascular disease or significant cardiovascular risk factors, orlistat (which acts by inhibiting gastrointestinal lipases without sympathomimetic activity) or GLP-1 receptor agonists (semaglutide 2.4 mg, liraglutide 3.0 mg, tirzepatide) are safer alternatives. 5, 6

• Orlistat produces mean weight loss of approximately 2.9 kg at 12 months without cardiovascular stimulation 5, 6
• GLP-1 receptor agonists provide superior weight-loss efficacy (≈21% with tirzepatide at 72 weeks vs. ≈5.1% with phentermine at 28 weeks) and have favorable cardiovascular safety profiles 5, 6